公开(公告)号：US20230110588A1

公开(公告)日：2023-04-13

申请号：US17721455

申请日：2022-04-15

Applicant: CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Lian Ni LEE ,  Senthil CHINNAKANNAN ,  Paul KLENERMAN

IPC: C12N15/86 ,  A61P35/00 ,  A61K45/06 ,  A61K38/47 ,  A61K38/17

Abstract: The present invention relates to an adenoviral vector or adeno-associated virus vector comprising a nucleotide sequence encoding a single cancer specific CD8+ T cell epitope, wherein the vector is capable of inducing an inflating memory CD8+ T cell response wherein said vector does not comprise a nucleic acid encoding further cancer specific T cell epitopes. It also relates to methods and uses of the vector.

公开(公告)号：US11453666B2

公开(公告)日：2022-09-27

申请号：US16826046

申请日：2020-03-20

Applicant: Cancer Research Technology Limited

Inventor： Martin Lee Stockley ,  Ellen Catherine Macdonald ,  Pritom Shah ,  Allan Jordan ,  James Hitchin ,  Niall Hamilton

IPC: A61P1/00 ,  A61P1/16 ,  A61P29/00 ,  A61P31/20 ,  A61P31/14 ,  A61P31/12 ,  A61P3/10 ,  A61P7/12 ,  A61P17/00 ,  A61P17/04 ,  A61P17/02 ,  A61P35/00 ,  A61P35/02 ,  A61P7/04 ,  A61P7/02 ,  A61P13/02 ,  A61P13/12 ,  A61P9/12 ,  A61P9/00 ,  A61P43/00 ,  A61P19/04 ,  A61K31/5025 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/404 ,  A61K31/551 ,  A61K31/55 ,  A61K31/496 ,  A61K31/4184 ,  A61K45/06 ,  C07D235/02 ,  C07D471/04 ,  A61K31/437

Abstract: The present invention relates to compounds of formula I wherein A1, A2, A3, R1, R2, R3, R4, R5, R6, L, Ar and Q are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.

公开(公告)号：US20220213207A9

公开(公告)日：2022-07-07

申请号：US17235174

申请日：2021-04-20

Applicant: Cancer Research Technology Limited

Inventor： Aymen Al-Shamkhani ,  Hak Tak Claude Chan ,  Mark Steven Cragg ,  Ruth Rosemary French ,  Martin John Glennie ,  Jane Elizabeth Willoughby

IPC: C07K16/28 ,  A61P35/02 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06

Abstract: The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof.

公开(公告)号：US20210276990A1

公开(公告)日：2021-09-09

申请号：US17124606

申请日：2020-12-17

Applicant: Cancer Research Technology Limited

Inventor： Ian Collins ,  Thomas Peter Matthews ,  Tatiana Faria Da Fonseca McHardy ,  James Osborne ,  Michael Lainchbury ,  Michael Ian Walton ,  Michelle Dawn Garrett

IPC: C07D413/14 ,  A61K31/4745 ,  C07D401/12 ,  C07D413/02 ,  A61K31/5377 ,  A61K9/00 ,  A61K45/06 ,  A61K31/7068

Abstract: The present invention pertains generally to the field of therapeutic compounds.
More specifically the present invention pertains to 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile compounds (referred to herein as “TFM compounds”) which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or a thymidylate synthase (TS) inhibitor; (d) a microtubule targeted agent; (e) ionising radiation; (f) an inhibitor of a mitosis regulator or a mitotic checkpoint regulator; (g) an inhibitor of a DNA damage signal transducer; or (h) an inhibitor of a DNA damage repair enzyme.

公开(公告)号：US11098121B2

公开(公告)日：2021-08-24

申请号：US15758165

申请日：2016-09-12

Applicant: CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Nicholas McGranahan ,  Rachel Rosenthal ,  Charles Swanton ,  Karl Peggs ,  Sergio Quezada

IPC: A61K39/395 ,  G16B30/00 ,  C07K16/28 ,  G16B40/00 ,  G01N33/574

Abstract: The present invention relates to methods for identifying a subject with cancer who is suitable for treatment with an immune checkpoint intervention, and to methods of treatment of such subjects. The invention further relates to a method for predicting or determining the prognosis of a subject with cancer.

公开(公告)号：US20210253583A1

公开(公告)日：2021-08-19

申请号：US17175780

申请日：2021-02-15

Applicant: CANCER RESEARCH TECHNOLOGY LIMITED ,  IP2IPO INNOVATIONS LIMITED ,  EMORY UNIVERSITY

Inventor： Alexander BONDKE ,  Sebastian KROLL ,  Anthony BARRETT ,  Matthew FUCHTER ,  Brian SLAFER ,  Simak ALI ,  Charles COOMBES ,  James Patrick SNYDER

IPC: C07D487/04 ,  A61K31/519 ,  A61P35/04

Abstract: Certain pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds that inhibit cycline dependent kinase (CDK) (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.) are disclosed. Pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions to inhibit CDK; to treat disorders associated with CDK such as those arising from an inappropriate activity, mutation, overexpression, or upstream pathway activation of CDK; or disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections; neurodegenerative disorders; ischaemia; renal diseases; and cardiovascular disorders are also disclosed. Optionally, the treatment further comprises simultaneous or sequential treatment with a further active agent, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.

公开(公告)号：US20210246131A1

公开(公告)日：2021-08-12

申请号：US17231164

申请日：2021-04-15

Applicant: Cancer Research Technology Limited

Inventor： Johannes Wilhelmus Maria Nissink ,  Maurice Raymond Verschoyle Finlay ,  Mark David Charles

IPC: C07D417/14

Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt thereof, where: Q can be 1,2,4-triazin-3-yl, pyridazin-3-yl, 6-methylpyridazin-3-yl, or 6-fluoropyridazin-3-yl; R1 can be hydrogen, methoxy, trifluoromethoxy, oxetan-3-yl, 3-fluoroazetidin-1-yl, 3-methoxyazetidin-1-yl, or 3,3-difluoroazetidin-1-yl; R2 can be hydrogen or fluoro; R3 can be hydrogen or methoxy; and R4 can be methoxy, ethoxy, or methoxymethyl; provided that when R1 is hydrogen, methoxy or trifluoromethoxy, then R3 is not hydrogen, and/or R4 is methoxymethyl. The compound of formula (I) can inhibit glutaminase, e.g., GLS1.

公开(公告)号：US11046688B2

公开(公告)日：2021-06-29

申请号：US16598717

申请日：2019-10-10

Applicant: Cancer Research Technology Limited

Inventor： Swen Hoelder ,  Julian Blagg ,  Savade Solanki ,  Hannah Woodward ,  Sebastien Gaston Andre Naud ,  Vassilios Bavetsias ,  Peter Sheldrake ,  Paolo Innocenti ,  Kwai-Ming J. Cheung ,  Butrus Atrash

IPC: A61K31/519 ,  C07D471/04 ,  C07D401/14 ,  C07D413/14 ,  C07D401/04 ,  C07D405/04 ,  C07D519/00

Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

公开(公告)号：US20210101887A1

公开(公告)日：2021-04-08

申请号：US16498207

申请日：2018-03-28

Applicant: ASTEX THERAPEUTICS LIMITED ,  CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Steven HOWARD ,  Benjamin David CONS ,  Jeffrey David ST. DENIS ,  Charlotte Mary GRIFFITHS-JONES ,  Steven Douglas HISCOCK ,  Rhian Sara HOLVEY ,  Alan Richard BURNS ,  David COUSIN ,  Hannah Louise DEXTER ,  Guillaume François PARRA ,  John Paul WATTS ,  Robert JEWELL ,  Jennifer Ann STOCKWELL ,  Kim Louise HIRST ,  Isabelle Anne LEMASSON ,  David John NASH ,  James Daniel OSBORNE ,  Jonas Calleja PRIEDE ,  Nicholas Paul RICHARDS ,  Aaron Michael DUMAS ,  Brian Christopher BISHOP ,  David PARRY-JONES ,  Jeremy Peter SCOTT ,  Meenakshi Sundaram SHANMUGHAM ,  Peter Richard MULLENS ,  David Charles LATHBURY ,  Darren James DIXON ,  Matthew James GAUNT

IPC: C07D405/06

Abstract: The invention relates to processes for preparing isoindolin-1-one derivatives, and in particular processes for preparing (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. The invention also relates to crystalline forms of the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid and its salts.

公开(公告)号：US10954251B2

公开(公告)日：2021-03-23

申请号：US16212582

申请日：2018-12-06

Applicant: Cancer Research Technology Limited

Inventor： Bruce D. Dorsey ,  Keith S. Learn ,  Emma L. Morris ,  Gregory R. Ott ,  Jonathan R. A. Roffey ,  Christelle N. Soudy ,  Jason C. Wagner

IPC: C07D495/04 ,  C07D495/20 ,  C07D495/14 ,  C07F7/08 ,  C07D519/00

Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have a PKC inhibitory activity, and may be used to treat proliferative disorders.